Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents

Wiley - Tập 57 Số 4 - Trang 639-647 - 2007
Jürgen Braun1, Xenofon Baraliakos, Joachim Listing, John C. Davis, D. van der Heijde, Hildrun Haibel, Martín Rudwaleit, Joachim Sieper
1Ruhr-University Bochum, Germany. [email protected]

Tóm tắt

AbstractObjectiveAnkylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti–tumor necrosis factor (anti‐TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative colitis [UC]). The purpose our study was to analyze the incidence of flares and new onset of IBD in patients with AS treated with anti‐TNF agents.MethodsData from 9 trials, 7 placebo‐controlled trials and 2 open studies, were analyzed.ResultsData were available on 419 AS patients exposed to etanercept (625 patient‐years), 366 exposed to infliximab (618 patient‐years), 295 exposed to adalimumab (132 patient‐years), and 434 placebo patients (150 patient‐years). A history of IBD was reported in 76 of 1,130 patients (6.7%). There were 2 reports of IBD while receiving placebo (1.3 per 100 patient‐years), 1 while receiving infliximab, and 3 while receiving adalimumab. Among the 14 IBD cases receiving etanercept (2.2 per 100 patient‐years) there were 8 CD and 6 UC cases, significantly different from infliximab (P = 0.01) but not from placebo. Patients with a history of IBD had an IBD flare odds ratio of 18.0 (95% confidence interval [95% CI] 2–154) while taking etanercept and 4.2 (95% CI 0.4–44) while taking adalimumab, in comparison with infliximab. The incidence rates of new onset of IBD showed no significant difference between etanercept (0.8 per 100 patient‐years) and placebo (0.5 per 100 patient‐years).ConclusionNew onset and flare of IBD are infrequent events in AS patients receiving anti‐TNF therapy. Infliximab (but not etanercept) largely prevents IBD activity. More data are required for adalimumab. The incidence of new onset of IBD was statistically not different from placebo for all anti‐TNF agents.

Từ khóa


Tài liệu tham khảo

10.1002/art.1780380407

Edmunds L, 1991, Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis, J Rheumatol, 18, 696

10.1007/PL00000223

10.1002/art.20977

10.1016/S0140-6736(02)08215-6

10.1002/art.11104

10.1136/ard.2004.025130

10.1093/rheumatology/keh584

10.1002/art.20852

10.1002/art.11017

10.1093/rheumatology/keh475

10.1002/art.11325

10.1002/art.20241

10.1136/ard.2004.035105

10.1002/art.21563

Braun J, 2006, Efficacy and safety of infliximab in patients with ankylosing spondylitis: 102 week results of the ASSERT trial, Ann Rheum Dis, 65, 87

10.1002/art.21913

10.1053/gast.2001.28674

10.1016/S0016-5085(99)70224-6

10.1016/S0140-6736(02)08512-4

Rutgeerts P, 2005, A randomized placebo‐controlled trial of infliximab for active ulcerative colitis: the ACT I trial, Gastroenterology, 128, A105

10.1056/NEJMoa050516

10.1136/ard.62.1.74

Oh J, 2005, Development of Crohn's disease in a patient taking etanercept, J Rheumatol, 32, 752

10.1097/00054725-200309000-00007

Stone M, 2001, Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis, J Rheumatol, 28, 1605

10.1056/NEJMoa012664

10.1136/ard.2004.020875

10.1002/art.21197

10.1093/oxfordjournals.aje.a009735

10.1002/art.1780370105

Braun J, 2006, The incidence of flares or new onsets of inflammatory bowel disease in patients with ankylosing spondylitis exposed to anti‐TNFα therapy, Ann Rheum Dis, 65, 86

10.1016/S1542-3565(05)00980-8

10.1111/j.1365-2036.2004.01944.x

10.1136/bmj.305.6844.20

10.1053/j.gastro.2005.11.030

10.1002/art.21588

Mielants H, 1991, Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study, J Rheumatol, 18, 1542

10.1007/s11894-000-0006-z

10.1097/00054725-200105000-00002

10.1016/j.semarthrit.2005.01.006

10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H

Baeten D, 2002, Influence of the gut and cytokine patterns in spondyloarthropathy, Clin Exp Rheumatol, 20, S38

10.1016/S0140-6736(00)04954-0

10.1136/ard.2004.032268

10.1056/NEJMoa030409

10.1016/S0140-6736(00)02530-7

Gladman D, 2006, Adalimumab is efficacious in treating skin disease in psoriatic arthritis: subanalysis by severity of psoriasis in ADEPT, Ann Rheum Dis, 65, 639

Choy E, 2006, Adalimumab is efficacious in treating joint disease in early and established psoriatic arthritis: subanalysis of ADEPT, Ann Rheum Dis, 65, 211

Thông tin
Thông tin xuất bản

Wiley

Tập 57 Số 4

639-647

Thông tin tác giả